OR WAIT null SECS
© 2021 MJH Life Sciences and BioPharm International. All rights reserved.
© 2021 MJH Life Sciences™ and BioPharm International. All rights reserved.
Better coordination in development and review of vaccines is needed.
Advances in technology are accelerating the development and manufacture of subunit vaccines.
Contract manufacturers play a key role in the production of lipid nanoparticles for RNA vaccines.
December 03, 2021
Moderna’s agreement with the UK government includes 29 million COVID-19 vaccine doses for delivery in 2022 and 31 million doses for delivery in 2023.
December 01, 2021
Partnerships formed during the COVID-19 pandemic have provided a platform for change in assay development and transfers that should continue in the future.
November 29, 2021
Samsung Biologics, GreenLight Biosciences, and Environmental Impact Acquisition Corp. have partnered to advance GreenLight’s mRNA COVID-19 vaccine candidate.
The companies are testing their existing vaccines against the new variant of concern and are pursuing variant-specific versions.
The Comirnaty vaccine received a positive opinion from the EMA’s CHMP for children five to under 12 years of age.
Samsung Biologics will manufacture GreenLight BioSciences' COVID-19 vaccine candidate for clinical trials and commercial sales.
November 19, 2021
FDA has amended its EUA for Pfizer-BioNTech’s and Moderna’s COVID-19 booster to include all individuals aged 18 or older.
EC has granted marketing authorization for Celltrion's Regkirona (regdanvimab, CT-P59) as a treatment for adults with COVID-19.
Novavax has announced that EMA has started its review of a conditional marketing authorization application for its COVID-19 vaccine, NVX-CoV2373.
November 11, 2021
The agency is recommending the authorization of Ronapreve (casirivimab/imdevimab) and Regkirona (regdanvimab), two monoclonal antibody drugs, for treating COVID-19.